Ciprofloxacin is actively transported across bronchial lung epithelial cells using a calu-3 air interface cell model

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2535-2540

  Ong, Hui Xin ^a,b   Traini, Daniela ^a,b   Bebawy, Mary ^c   Young, Paul M ^a,b  

^a WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ORGANIC CATION TRANSPORTER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS EPITHELIUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; BRONCHI; CELL LINE; CIPROFLOXACIN; EPITHELIAL CELLS; HUMANS; LUNG; MODELS, BIOLOGICAL; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS;

EID: 84877842865     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00306-13     Document Type: Article

References (43)

1. Davis R, Markham A, Balfour J. 1996. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 51:1019-1074.
2. Eron LJ, Harvey L, Hixon DL, Poretz DM. 1985. Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria. Antimicrob. Agents Chemother. 28:308-310.
3. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, O'Donnell A, Sahn SA, Smith LJ, Stewart JO, Abuan T, Tully H, Van Dalfsen J, Wells CD, Quan J. 2000. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit. Care Med. 162:481-485.
4. Geller DE. 2009. Aerosol antibiotics in cystic fibrosis. Respir. Care 54: 658-670.
5. Hopf G, Böcker R, Estler CJ, Radtke H, Floh H. 1988. Concentration of ciprofloxacin in human serum, lung and pleural tissues and fluids during and after lung surgery. Infection 16:29-30.
6. Rohwedder R, Bergan T, Caruso E, Thorsteinsson S, Torre H, Scholl H. 1991. Penetration of ciprofloxacin and metabolites into human lung, bronchial and pleural tissue after 250 and 500 mg oral ciprofloxacin. Chemotherapy 37:229-238.
7. Cavet ME, West M, Simmons NL. 1997. Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells. Antimicrob. Agents Chemother. 41:2693-2698.
8. Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ. 1991. Antibiotic tissue penetration and its relevance: Impact of tissue penetration on infection response. Antimicrob. Agents Chemother. 35:1953-1959.
9. Adi H, Young PM, Chan HK, Agus H, Traini D. 2010. Co-spraydried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur. J. Pharm. Sci. 40:239-247.
10. Ong HX, Traini D, Cipolla D, Gonda I, Bebawy M, Agus H, Young PM. Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. Pharm. Res. 2012:1-12.
11. Conley J, Yang H, Wilson T, Blasetti K, Di Ninno V, Schnell G, Wong JP. 1997. Aerosol delivery of liposome-encapsulated ciprofloxacin: Aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob. Agents Chemother. 41:1288-1292.
12. Cipolla DC, Redelmeier T, Eastman S, Bruinenberg P, Gonda I (ed). 2010. Liposomes, niosomes and proniosomes-a critical update of their (commercial) development as inhaled products, p 41-54. In Proceedings of RDD Europe 2011, Berlin, Germany.
13. Davis Healthcare International Publishing, Rover Grove, IL. 13. Endter S, Francombe D, Ehrhardt C, Gumbleton M. 2009. RT-PCR analysis of ABC, SLC and SLCO drug transporters in human lung epithelial cell models. J. Pharm. Pharmacol. 61:583-591.
14. Bosquillon C. 2010. Drug transporters in the lung, do they play a role in the biopharmaceutics of inhaled drugs? J. Pharm. Sci. 99:2240-2255.
15. Mathias NR, Timoszyk J, Stetsko PI, Megill JR, Smith RL, Wall DA. 2002. Permeability characteristics of Calu-3 human bronchial epithelial cells: In vitro-in vivo correlation to predict lung absorption in rats. J. Drug Target. 10:31-40.
16. Ong HX, Traini D, Bebawy M, Young PM. 2011. Epithelial profiling of antibiotic controlled release respiratory formulations. Pharm. Res. 28: 2327-2338.
17. Haghi M, Young PM, Traini D, Jaiswal R, Gong J, Bebawy M. 2010. Time-and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. Drug Dev. Ind. Pharm. 36:1207-1214.
18. Bur M, Lehr C-M. 2008. Pulmonary cell culture models to study the safety and efficacy of innovative aerosol medicines. Expert Opin. Drug Deliv. 5:641-652.
19. Grainger CI, Greenwell LL, Lockley DJ, Martin GP, Forbes B. 2006. Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier. Pharm. Res. 23:1482-1490.
20. Haghi M, Traini D, Bebawy M, Young PM. 2012. Deposition, diffusion and transport mechanism of dry powder microparticulate salbutamol, at the respiratory epithelia. Mol. Pharm. 9:1717-1726.
21. Hamilton KO, Backstrom G, Yazdanian MA, Audus KL. 2001. P-glycoprotein efflux pump expression and activity in Calu-3 cells. J. Pharm. Sci. 90:647-658.
22. Lehmann T, Köhler C, Weidauer E, Taege C, Foth H. 2001. Expression of MRP1 and related transporters in human lung cells in culture. Toxicology 167:59-72.
23. Ehrhardt C, Kneuer C, Bies C, Lehr CM, Kim KJ, Bakowsky U. 2005. Salbutamol is actively absorbed across human bronchial epithelial cell layers. Pulm. Pharmacol. Ther. 18:165-170.
24. Brillault J, De Castro WV, Harnois T, Kitzis A, Olivier JC, Couet W. 2009. P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model. Antimicrob. Agents Chemother. 53:1457-1462.
25. Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, Tsuji A. 2006. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab. Dispos. 34:1423-1431.
26. Vasudevan D, Bruland GL, Torrance BS, Upchurch VG, MacKay AA. 2009. pH-dependent ciprofloxacin sorption to soils: Interaction mechanisms and soil factors influencing sorption. Geoderma 151:68-76.
27. Drori S, Eytan GD, Assaraf YG. 1995. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur. J. Biochem. 228:1020-1029.
28. Dönmez Y, Akhmetova L, Işeri OD, Kars MD, Gündüz U. 2011. Effect ofMDRmodulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells. Cancer Chemother. Pharmacol. 67:823-828.
29. Callaghan R, Stafford A, Epand RM. 1993. Increased accumulation of drugs in a multidrug resistant cell line by alteration of membrane biophysical properties. Biochim. Biophys. Acta 1175:277-282.
30. Ohashi R, Tamai I, Nezu J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A. 2001. Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol. Pharmacol. 59:358-366.
31. Hirsch-Ernst KI, Ziemann C, Rustenbeck I, Kahl GF. 2001. Inhibitors of mdr1-dependent transport activity delay accumulation of the mdr1 substrate rhodamine 123 in primary rat hepatocyte cultures. Toxicology 167: 47-57.
32. Bakośe, Evers R, Sinkó E, Váradi A, Borst P, Sarkadi B. 2000. Interactions of the human multidrug resistance proteinsMRP1andMRP2 with organic anions. Mol. Pharmacol. 57:760-768.
33. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G. 1999. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59:2532-2535.
34. Gibbs J, Thomas S. 2002. The distribution of the anti-HIV drug, 2= 3=-dideoxycytidine (ddC), across the blood-brain and bloodcerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J. Neurosci. 80:392-404.
35. Gutman J, Kachur S, Slutsker L, Nzila A, Mutabingwa T. 2012. Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy. Malar. J. 11:39. doi:10.1186/1475-2875-11-39.
36. Hirano T, Yasuda S, Osaka Y, Asari M, Kobayashi M, Itagaki S, Iseki K. 2008. The inhibitory effects of fluoroquinolones on L-carnitine transport in placental cell line BeWo. Int. J. Pharm. 351:113-118.
37. Griffiths NM, Hirst BH, Simmons NL. 1994. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway? J. Pharmacol. Exp. Ther. 269:496-502.
38. Griffiths NM, Hirst BH, Simmons NL. 1993. Active secretion of the fluoroquinolone ciprofloxacin by human intestinal epithelial Caco-2 cell layers. Br. J. Pharmacol. 108:575-576.
39. Cavet M, West M, Simmons N. 1997. Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol. 121:1567-1578.
40. Yamaguchi H, Yano I, Saito H, Inui K. 2004. Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm. Res. 21:330-338.
41. Breda SA, Guzman ML, Confalonieri A, Gonzalez C, Sparo M, Manzo RH, Bruni SS, Olivera ME. 2013. Systemic exposure, tissue distribution, and disease evolution of a high solubility ciprofloxacin-aluminum complex in a murine model of septicemia induced by Salmonella enterica serotype Enteritidis. Mol. Pharm. 10:598-605.
42. Chono S, Tanino T, Seki T, Morimoto K. 2008. Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects. Drug Dev. Ind. Pharm. 34:1090-1096.
43. Neu HC, Fang W, Gu JW, Chin NX. 1992. In vitro activity of OPC-17116. Antimicrob. Agents Chemother. 36:1310-1315.